Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For a non-UK medical device manufacturer planning for market access in 2026, what are the primary factors that influence the cost of engaging a UK Responsible Person (UKRP)? Beyond a simple flat fee, ...
With the European Union implementing significant updates to its cosmetics framework, including new substance restrictions and digital labeling initiatives slated for enforcement through 2026, how shou...
For non-EU manufacturers placing medical devices on the European market, the selection of an EU Authorized Representative (EUAR) is a critical compliance step under the Medical Device Regulation (MDR)...
For non-EU based medical device manufacturers, particularly those developing Software as a Medical Device (SaMD) or connected health products that process personal data of EU residents, selecting a Eu...
When a non-EU medical device or SaMD company processes the personal data of individuals in the European Union, appointing a GDPR Article 27 Representative is a mandatory compliance step. However, sele...
Under the EU Medical Device Regulation (MDR), the role of the Authorized Representative (AR) has evolved from a simple liaison to a legally liable partner. For a non-EU manufacturer of a device, such ...
As the UK medical device regulatory framework continues to evolve, with significant deadlines anticipated around 2026, non-UK manufacturers face the critical task of appointing a UK Responsible Person...
As the UK's regulatory landscape for medical devices evolves, manufacturers based outside the UK must appoint a UK Responsible Person (UKRP) to place devices on the Great Britain market. Beyond the ba...
When a non-EU cosmetics manufacturer plans to enter the European market, selecting a Responsible Person (RP) is a critical compliance step. Given the evolving regulatory landscape, how can a company m...
When a medical device manufacturer, particularly one based outside the European Union, needs to appoint a regulatory representative, what are the critical factors to assess beyond basic compliance? Wh...
For non-EU developers of AI-enabled medical technology, navigating European representation requirements is becoming increasingly complex. The GDPR's mandate for an Article 27 Representative is well-es...
For non-EU manufacturers of AI-enabled medical devices or SaMD, the upcoming EU AI Act introduces a new layer of complexity on top of existing GDPR obligations. While GDPR Article 27 requires a repres...
For non-EU providers of AI systems, particularly those classified as high-risk under the EU AI Act, appointing an EU Authorized Representative (AR) is a critical compliance step. While specific fees a...
With the introduction of the EU AI Act, non-EU providers of AI systems, particularly those classified as high-risk, face the new obligation of appointing an EU-based Authorized Representative (AR). Be...
For foreign medical device establishments planning for U.S. market entry, understanding the full scope of associated costs is critical. While FDA user fees, such as those for establishment registratio...
With various regulatory deadlines and user fee schedules being updated, many foreign medical device establishments are asking: what are the FDA requirements for a U.S. Agent in 2026, and are any signi...
As medical devices become increasingly interconnected, how can sponsors effectively integrate cybersecurity management into their existing Quality Management System (QMS) to align with evolving regula...
With significant updates to EU cosmetic regulations anticipated for 2026, including changes related to the CLP Regulation and INCI nomenclature, how should a non-EU brand structure its evaluation proc...
For a non-EU company launching an AI-powered Software as a Medical Device (SaMD) in Europe, how can it strategically select a GDPR Article 27 Representative that is truly fit for purpose in a complex ...
For a non-EU manufacturer of an AI-enabled medical device, appointing an in-region representative is a critical step for market entry. However, with the convergence of medical device regulations, stri...